8-K: Actuate Reports Positive Elraglusib Pancreatic Cancer Data

Actuate Therapeutics announced positive follow-up data from its Phase 2 trial of elraglusib, showing extended overall survival benefit in metastatic pancreatic cancer patients.

Summary

• The Phase 2 study (Actuate-1801 Part 3B) of elraglusib combined with gemcitabine/nab-paclitaxel (GnP) for first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) met its primary endpoint.
• The elraglusib combination significantly improved overall survival compared to GnP alone, reducing the risk of death by 38%.
• Median overall survival (OS) was 10.1 months for the elraglusib/GnP arm versus 7.2 months for the GnP alone arm (p=0.02, HR=0.62).
• The 12-month survival rate doubled to 44.4% in the elraglusib/GnP arm compared to 22.3% in the GnP arm.
• The 24-month survival rate increased fivefold to 12.9% in the elraglusib/GnP arm compared to 2.6% in the GnP arm, indicating potential for long-term clinical benefit.
• As of November 2025, seventeen patients remain alive in the elraglusib/GnP arm, with three having passed the 24-month mark on first-line treatment, while no patients remain on GnP treatment alone.
• The safety and tolerability profile of elraglusib was consistent with previously reported data at the 9.3 mg/kg dose, with no new safety signals identified.
• Serious treatment-emergent adverse events (TEAEs) were similar between the elraglusib/GnP (56.1%) and GnP alone (56.4%) arms.
• TEAEs resulting in death were similar: 12.3% for elraglusib/GnP and 16.7% for GnP alone.
• Grade-3 or higher TEAEs leading to stoppage of any study drug were similar: 16.8% for elraglusib/GnP and 21.8% for GnP alone.
• Genomic biomarkers, including KRAS or ARID1A mutations, were identified as potential predictive biomarkers of overall survival in the elraglusib/GnP arm.
• Immunological biomarkers (CD8+, Granzyme B+ cells, and NK cells) were increased in tumors from elraglusib/GnP-treated patients, suggesting improved anti-tumor immune response.

Sentiment

Score: 8

Explanation: The clinical trial results are highly positive, showing statistically significant and clinically meaningful improvements in overall survival for a difficult-to-treat cancer. This is a major scientific and medical achievement. However, the company explicitly states a 'going concern' risk and the immediate need for additional capital beyond Q2 2026, which introduces significant financial uncertainty.

Positives

• Statistically significant improvement in median overall survival (10.1 months vs. 7.2 months, p=0.02, HR=0.62).
• Doubled 12-month survival rate (44.4% vs. 22.3%) with elraglusib combination therapy.
• Fivefold increase in 24-month survival rate (12.9% vs. 2.6%) with elraglusib combination therapy.
• Elraglusib combination reduced the risk of death by 38% compared to chemotherapy alone.
• Increased durable survival observed beyond 24 months, with three patients in the elraglusib arm surpassing this milestone.
• Manageable safety profile consistent with previous data, with no new safety signals identified.
• Identification of potential predictive genomic and immunological biomarkers for future study and patient selection.

Risks

• Preliminary and unpublished data may be subject to change and further interpretation following the availability of more data or a more comprehensive review.
• Clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes.
• Results of prior preclinical studies, early clinical trials, and sub-group studies are not necessarily predictive of future results and may not correlate with improved responses.
• Elraglusib may not achieve positive clinical results or favorable preclinical results or receive regulatory approval on a timely basis, if at all.
• The company may not successfully enroll additional patients or establish or advance plans for further development, including through conversations with regulatory bodies like the FDA or EMA.
• Elraglusib could be associated with side effects, adverse events, or other properties or safety risks, which could delay or preclude regulatory approval, cause suspension or discontinuation of clinical trials, or result in other negative consequences.
• Reliance on third parties to conduct non-clinical studies and clinical trials.
• Reliance on third-party licensors and the ability to preserve and protect intellectual property rights.
• Significant competition from other biotechnology and pharmaceutical companies.
• The company's financial condition raises substantial doubt as to its ability to continue as a going concern.
• The company requires additional capital to finance operations beyond the second quarter of fiscal year 2026.
• A failure to obtain necessary capital in the near term on acceptable terms, or at all, could force the company to delay, limit, reduce, or terminate its development programs, commercialization efforts, or other operations.

Future Outlook

The company intends to build upon the positive Phase 2 data to further advance elraglusib for patients with metastatic pancreatic cancer. There is also potential for future clinical studies exploring novel drug combinations based on identified genomic biomarkers. However, the company's ability to fund these development activities beyond the second quarter of fiscal year 2026 is uncertain, as it requires additional capital to continue as a going concern.

Management Comments

• Dr. Devalingam Mahalingam, MD, PhD: "The results from this Phase 2 study suggest that adding elraglusib to standard gemcitabine and nab-paclitaxel chemotherapy may improve survival outcomes while maintaining a manageable safety profile. The scope of this trial, which enrolled 286 patients across 60 sites in six countries, underscores the robustness of the dataset."
• Dan Schmitt, Chief Executive Officer of Actuate Therapeutics: "In this randomized Phase 2 study, the addition of elraglusib to gemcitabine and nab-paclitaxel resulted in a meaningful improvement in overall survival compared with chemotherapy alone. Current patient survival for metastatic pancreatic cancer is less than 12 months, so our findings are especially encouraging. We look forward to building from this data and continuing to advance elraglusib for patients with this devastating disease."

Industry Context

Metastatic pancreatic cancer represents a high unmet medical need, being one of the most challenging cancers to treat with limited effective first-line options and typical patient survival of less than 12 months. The positive results for elraglusib, demonstrating statistically significant and clinically meaningful improvements in overall survival, including a fivefold increase in the 24-month survival rate, position it as a potentially significant advancement in this difficult disease area, offering new hope for patients.

Comparison to Industry Standards

• Current patient survival for metastatic pancreatic cancer is less than 12 months; elraglusib/GnP achieved a median OS of 10.1 months, a significant improvement over the 7.2 months for GnP alone.
• The 12-month survival rate of 44.4% for elraglusib/GnP is double that of GnP alone (22.3%), indicating a substantial improvement over standard care.
• The 24-month survival rate of 12.9% for elraglusib/GnP is five times higher than GnP alone (2.6%), highlighting a notable advance in long-term survival for this patient population.
• The 38% reduction in the risk of death with elraglusib combination therapy compared to chemotherapy alone demonstrates a strong efficacy signal against existing treatments for this aggressive cancer.

Stakeholder Impact

• Shareholders: Positive clinical data could increase investor confidence and potentially share price, but the explicit 'going concern' warning introduces significant financial risk.
• Patients: The positive results offer hope for improved treatment outcomes for metastatic pancreatic cancer, a disease with a high unmet medical need.
• Medical Community: The data presented at ASCO GI 2026 contributes to the scientific understanding of mPDAC treatment and the potential role of GSK-3 inhibition.
• Employees: Continued development of elraglusib could secure future employment, but the financial uncertainty poses a risk to job security.

Next Steps

• Building from the positive Phase 2 data to continue advancing elraglusib for patients with metastatic pancreatic cancer.
• Exploring potential novel drug combinations for future clinical studies based on identified genomic biomarkers (KRAS, ARID1A).
• Engaging in conversations with regulatory bodies like the FDA or EMA to establish and advance plans for further development.

Key Dates

Recommendation

While the clinical data for elraglusib in metastatic pancreatic cancer is exceptionally strong and represents a significant medical advancement, the explicit disclosure of a 'going concern' risk and the immediate need for capital beyond Q2 2026 introduces substantial financial uncertainty. The positive clinical news is balanced by severe funding risks. An investor should hold, awaiting clarity on the company's financing strategy before making further investment decisions, as the potential for a capital raise or even insolvency could significantly impact share value despite the promising drug candidate.

Keywords

elraglusib, pancreatic cancer, metastatic pancreatic ductal adenocarcinoma, mPDAC, Phase 2 trial, overall survival, GSK-3 inhibitor, oncology, biopharmaceutical, clinical-stage, ASCO GI, gemcitabine, nab-paclitaxel, chemotherapy, biomarker, Actuate Therapeutics